½ðºÌÓéÀÖ³Ç

At the AD/PD Congress, one of the leading global events for advancing science in Alzheimer¡¯s and Parkinson¡¯s diseases, we are reaffirming our commitment to tackling the challenges of these devastating neurodegenerative diseases. The conference provides an invaluable platform to connect with the scientific community, fuel dialogues that spark innovation, and drive progress in understanding the underlying mechanisms of these complex conditions.  

Neurodegenerative diseases like Alzheimer¡¯s and Parkinson¡¯s present an urgent, unmet medical need. These conditions profoundly affect millions of individuals and their families worldwide, often robbing them of independence and quality of life. We recognize that current solutions often fall short in providing comprehensive care, and we are dedicated to researching to bridge these gaps with innovative solutions. To develop solutions effectively, we must first uncover the mysteries behind their onset and progression.  

½ðºÌÓéÀֳǡ¯s Parkinson's research program includes investigating mechanisms to inhibit the propagation of alpha-synuclein ¨C a process believed to underlie the spread of neurodegeneration. Alongside this, we are advancing research into innovative therapies for symptom control, recognizing the diverse needs of each patient throughout their disease trajectory, from early to advanced stages.

We firmly believe that the patient voice is essential in shaping meaningful research and therapies. By prioritizing patient-led initiatives and collaborating directly with those affected, we ensure that our work reflects their needs, experiences, and hopes for the future. The Patient Engagement and Care Progression Research (PECPR) initiative, established in 2021 is a collaborative effort to bring the patient community into the heart of early research and clinical development. The initiative strives to improve patient outcomes by working together on a patient-centered research model, embedding patient involvement throughout ½ðºÌÓéÀֳǡ¯s Parkinson¡¯s drug development portfolio, and fostering global collaboration to advance Parkinson¡¯s research.

In Alzheimer's, we're hoping to find therapies that can slow the progression of the disease, and recent data from our development program is also on show at AD/PD. Alzheimer¡¯s disease occurs when harmful plaques and tangles comprised of ¦Â-amyloid and tau protein build up in the brain, disrupting its function and leading to cognitive decline and dementia.

By progressing the science, working together and listening to the patient voice, we aim to move closer to a world where no family has to face the burden of neurodegenerative disease alone. To every scientist and researcher who joined us at AD/PD ¡ª thank you. Your dedication and ideas inspire hope and progress. Together, we are working towards a better future in neurodegenerative science, for patients now and in the future.